These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

199 related items for PubMed ID: 14998623

  • 1. Matrix metalloproteinase-9 contributes to human atrial remodeling during atrial fibrillation.
    Nakano Y, Niida S, Dote K, Takenaka S, Hirao H, Miura F, Ishida M, Shingu T, Sueda T, Yoshizumi M, Chayama K.
    J Am Coll Cardiol; 2004 Mar 03; 43(5):818-25. PubMed ID: 14998623
    [Abstract] [Full Text] [Related]

  • 2. [Effects of matrix metalloproteinase-9 and tissue inhibitor-1 of metalloproteinase expression on atrial structural remodeling during chronic atrial fibrillation].
    Zhu H, Zhang W, Guo CH, Zhang G, Zhang WD, Zhong M, Yang GR, Ge ZM, Zhang Y.
    Zhonghua Yi Xue Za Zhi; 2005 Jan 05; 85(1):45-8. PubMed ID: 15808077
    [Abstract] [Full Text] [Related]

  • 3. Matrix metalloproteinases and atrial remodeling in patients with mitral valve disease and atrial fibrillation.
    Anné W, Willems R, Roskams T, Sergeant P, Herijgers P, Holemans P, Ector H, Heidbüchel H.
    Cardiovasc Res; 2005 Sep 01; 67(4):655-66. PubMed ID: 15913581
    [Abstract] [Full Text] [Related]

  • 4. [Changes in gelatinases expression and activity in human atria during atrial fibrillation].
    Ke D, Xu CX, Zhang JC, Chen L, Lin YZ, Lin LF, Hu XZ.
    Zhonghua Xin Xue Guan Bing Za Zhi; 2005 Feb 01; 33(2):137-42. PubMed ID: 15924808
    [Abstract] [Full Text] [Related]

  • 5. Upregulation of matrix metalloproteinase-9 and tissue inhibitors of metalloproteinases in rapid atrial pacing-induced atrial fibrillation.
    Chen CL, Huang SK, Lin JL, Lai LP, Lai SC, Liu CW, Chen WC, Wen CH, Lin CS.
    J Mol Cell Cardiol; 2008 Dec 01; 45(6):742-53. PubMed ID: 18692064
    [Abstract] [Full Text] [Related]

  • 6. [Role of matrix metalloproteinase and tissue inhibitor of metalloproteinase in atrial structural remodeling in patients with atrial fibrillation].
    Wang W, Wu PS, Yang XL.
    Nan Fang Yi Ke Da Xue Xue Bao; 2010 May 01; 30(5):1160-2. PubMed ID: 20501421
    [Abstract] [Full Text] [Related]

  • 7. Matrix metalloproteinase-9/tissue inhibitors of metalloproteinase-1 expression and atrial structural remodeling in a dog model of atrial fibrillation: inhibition with angiotensin-converting enzyme.
    Zhang W, Zhong M, Yang GR, Li JP, Guo C, Wang Z, Zhang Y.
    Cardiovasc Pathol; 2008 May 01; 17(6):399-409. PubMed ID: 18706834
    [Abstract] [Full Text] [Related]

  • 8. Role of matrix metalloproteinases 1, 2, and 9 and tissue inhibitor of matrix metalloproteinase-1 in chronic venous insufficiency.
    Saito S, Trovato MJ, You R, Lal BK, Fasehun F, Padberg FT, Hobson RW, Durán WN, Pappas PJ.
    J Vasc Surg; 2001 Nov 01; 34(5):930-8. PubMed ID: 11700497
    [Abstract] [Full Text] [Related]

  • 9. [Clinical on molecular basis of atrial fibrosis in patients with atrial fibrillation investigation].
    Ke D, Xu CX, Lin YZ, Zhang JC, Chen L, Lin LF, Hu XZ.
    Zhonghua Xin Xue Guan Bing Za Zhi; 2005 May 01; 33(5):459-63. PubMed ID: 15932710
    [Abstract] [Full Text] [Related]

  • 10. Selective induction of matrix metalloproteinases and tissue inhibitor of metalloproteinases in atrial and ventricular myocardium in patients with atrial fibrillation.
    Mukherjee R, Herron AR, Lowry AS, Stroud RE, Stroud MR, Wharton JM, Ikonomidis JS, Crumbley AJ, Spinale FG, Gold MR.
    Am J Cardiol; 2006 Feb 15; 97(4):532-7. PubMed ID: 16461051
    [Abstract] [Full Text] [Related]

  • 11. [The relation between angiotensin II receptors 1 and 2, and CYP11B2 and atrial structural remodeling in patients with atrial fibrillation].
    Wu YQ, Wang XD, Fang H, Wang YL, Zhang YC, Su LJ.
    Zhonghua Yi Xue Za Zhi; 2007 Aug 28; 87(32):2281-4. PubMed ID: 18001553
    [Abstract] [Full Text] [Related]

  • 12. Differential gene expression during atrial structural remodeling in human left and right atrial appendages in atrial fibrillation.
    Zhu H, Zhang W, Zhong M, Zhang G, Zhang Y.
    Acta Biochim Biophys Sin (Shanghai); 2011 Jul 28; 43(7):535-41. PubMed ID: 21659381
    [Abstract] [Full Text] [Related]

  • 13. [Significance of imbalance between matrix metalloproteinases and tissue type inhibitor of metalloproteinases in renal tubulointerstitial lesions of aging rats].
    Chen RQ, Chen XM, Cui SW, Cai GY, Shi SZ, Xie YS, Lu Y, Peng LX.
    Zhonghua Yi Xue Za Zhi; 2004 Jun 02; 84(11):937-42. PubMed ID: 15329283
    [Abstract] [Full Text] [Related]

  • 14. Matrix metalloproteinase inhibition attenuates atrial remodeling and vulnerability to atrial fibrillation in a canine model of heart failure.
    Moe GW, Laurent G, Doumanovskaia L, Konig A, Hu X, Dorian P.
    J Card Fail; 2008 Nov 02; 14(9):768-76. PubMed ID: 18995182
    [Abstract] [Full Text] [Related]

  • 15. Decreased plasminogen activator inhibitor and tissue metalloproteinase inhibitor expression may promote increased metalloproteinase activity with increasing duration of human atrial fibrillation.
    Gramley F, Lorenzen J, Plisiene J, Rakauskas M, Benetis R, Schmid M, Autschbach R, Knackstedt C, Schimpf T, Mischke K, Gressner A, Hanrath P, Kelm M, Schauerte P.
    J Cardiovasc Electrophysiol; 2007 Sep 02; 18(10):1076-82. PubMed ID: 17655664
    [Abstract] [Full Text] [Related]

  • 16. Atrial extracellular matrix remodeling and the maintenance of atrial fibrillation.
    Xu J, Cui G, Esmailian F, Plunkett M, Marelli D, Ardehali A, Odim J, Laks H, Sen L.
    Circulation; 2004 Jan 27; 109(3):363-8. PubMed ID: 14732752
    [Abstract] [Full Text] [Related]

  • 17. Extracellular matrix alterations in patients with paroxysmal and persistent atrial fibrillation: biochemical assessment of collagen type-I turnover.
    Kallergis EM, Manios EG, Kanoupakis EM, Mavrakis HE, Arfanakis DA, Maliaraki NE, Lathourakis CE, Chlouverakis GI, Vardas PE.
    J Am Coll Cardiol; 2008 Jul 15; 52(3):211-5. PubMed ID: 18617070
    [Abstract] [Full Text] [Related]

  • 18. Effect of matrix metalloproteinase and their inhibitors on atrial myocardial structural remodeling.
    Wang W, Zhang HT, Yang XL.
    J Cardiovasc Med (Hagerstown); 2013 Apr 15; 14(4):265-9. PubMed ID: 22929563
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. [Expression of mineralocorticoid receptor and 11-beta-hydroxysteroid dehydrogenase type 2 in human atria during chronic atrial fibrillation: study of 25 cases].
    Pei DA, Li L, Xu ZY, Zou LJ, Zhang BR, Huang SD, Hao JH, Wang ZN, Lu FL.
    Zhonghua Yi Xue Za Zhi; 2007 Mar 27; 87(12):816-9. PubMed ID: 17565863
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.